Cepheid Company Profile (NASDAQ:CPHD)

About Cepheid

Cepheid logo

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Industry, Sector and Symbol:

Sector: Medical
Industry: Scientific & Technical Instruments
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: CPHD
CUSIP: 15670R10

Key Metrics:

Previous Close: $52.69
50 Day Moving Average: $43.67
200 Day Moving Average: $34.47
52-Week Range: $25.09 - $53.91
Trailing P/E Ratio: N/A
Foreward P/E Ratio: 86.38
P/E Growth: 6.39
Market Cap: $3.85B
Outstanding Shares: 73,007,000
Beta: 0.4

Profitability:

Net Margins: -8.78%
Return on Equity: -10.20%
Return on Assets: -4.61%

Debt:

Debt-to-Equity Ratio: 0.76%
Current Ratio: 3.79%
Quick Ratio: 2.74%

Additional Links:

Companies Related to Cepheid:

Consensus Ratings for Cepheid (NASDAQ:CPHD) (?)

Ratings Breakdown:	16 Hold Ratings, 5 Buy Ratings
Consensus Rating:	Hold (Score: 2.24)
Consensus Price Target:	$41.87 (20.54% downside)

Analysts' Ratings History for Cepheid (NASDAQ:CPHD)

Show:

Date	Firm	Action	Rating	Price Target
9/12/2016	Robert W. Baird	Downgrade	Outperform -> Neutral	$53.00
9/8/2016	Citigroup Inc.	Downgrade	Buy -> Neutral	$44.00 -> $53.00
9/7/2016	Barclays PLC	Boost Price Target	Equal Weight	$36.00 -> $52.00
9/7/2016	BTIG Research	Downgrade	Buy -> Neutral
9/7/2016	Cowen and Company	Downgrade	Outperform -> Market Perform
9/6/2016	Craig Hallum	Downgrade	Buy -> Hold
9/6/2016	Piper Jaffray Cos.	Downgrade	Overweight -> Neutral
9/6/2016	Needham & Company LLC	Downgrade	Buy -> Hold
8/17/2016	Jefferies Group	Boost Price Target	Hold	$28.00 -> $34.00
7/29/2016	JPMorgan Chase & Co.	Boost Price Target	Neutral	$32.00 -> $35.00
6/29/2016	Canaccord Genuity	Reiterated Rating	Hold	$32.00
6/15/2016	Morgan Stanley	Initiated Coverage	Equal Weight	$30.00
4/1/2016	Atlantic Securities	Upgrade	Neutral -> Overweight
3/28/2016	Wedbush	Lower Price Target	Outperform	$58.00 -> $55.00
2/3/2016	Stifel Nicolaus	Lower Price Target	Buy	$42.00 -> $38.00
2/3/2016	Leerink Swann	Reiterated Rating	Market Perform	$39.00 -> $33.00
1/6/2016	Avondale Partners	Initiated Coverage	Outperform	$46.00
12/2/2015	Wells Fargo & Co.	Downgrade	Outperform -> Market Perform
10/21/2015	Evercore ISI	Upgrade	Sell -> Hold	$44.50 -> $32.50
10/21/2015	Mizuho	Lower Price Target	Buy	$60.00 -> $42.00
10/14/2015	Goldman Sachs Group Inc.	Lower Price Target		$53.00 -> $30.00
10/14/2015	Raymond James Financial Inc.	Downgrade	Outperform -> Market Perform
7/26/2015	MKM Partners	Reiterated Rating	Buy	$65.00 -> $72.00
7/24/2015	Evercore Partners Inc.	Reiterated Rating	Hold -> Sell
4/26/2015	Cantor Fitzgerald	Reiterated Rating	Buy	$62.00
4/24/2015	JMP Securities	Boost Price Target	Market Outperform	$58.00 -> $67.00
1/30/2015	Oppenheimer Holdings Inc.	Boost Price Target	Outperform	$57.00 -> $60.00
12/30/2014	William Blair	Reiterated Rating	Buy
12/30/2014	Bank of America Corp.	Upgrade	Neutral -> Buy

(Data available from 9/29/2014 forward)

Earnings History for Cepheid (NASDAQ:CPHD)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/12/2016
7/28/2016	Q216	($0.14)	$0.05	$145.82 million	$146.00 million	View	Listen
4/28/2016	Q116	$0.01	$0.08	$140.35 million	$144.80 million	View	N/A
2/2/2016	Q415	($0.20)	$0.07	$146.95 million	$147.00 million	View	N/A
10/20/2015	Q3	($0.31)	($0.13)	$126.81 million	$126.50 million	View	Listen
7/23/2015	Q215	($0.21)	($0.06)	$130.70 million	$132.50 million	View	Listen
4/23/2015	Q115	($0.16)	$0.01	$125.50 million	$132.60 million	View	N/A
1/29/2015	Q414	($0.13)	$0.11	$125.34 million	$131.50 million	View	N/A
10/16/2014	Q314	($0.16)	$0.06	$110.10 million	$115.20 million	View	Listen
7/17/2014	Q214	($0.13)	$0.03	$115.47 million	$116.50 million	View	N/A
4/17/2014	Q114	($0.17)	($0.01)	$104.90 million	$106.90 million	View	N/A
1/31/2014	Q413	($0.11)	($0.15)	$102.17 million	$113.30 million	View	N/A
10/17/2013	Q313	($0.11)	($0.20)	$93.70 million	$100.10 million	View	N/A
7/18/2013	Q2 2013	$0.04	$0.02	$92.57 million	$96.00 million	View	N/A
4/18/2013	Q1 2013	$0.10	$0.11	$89.12 million	$91.90 million	View	N/A
1/24/2013	Q4 2012	$0.11	$0.20	$92.87 million	$92.40 million	View	N/A
10/18/2012		($0.07)	($0.32)			View	N/A
7/19/2012		$0.11	$0.11			View	N/A
4/19/2012		($0.01)	($0.08)			View	N/A
1/26/2012		($0.02)	($0.03)			View	N/A
10/20/2011		$0.02	$0.03			View	N/A
7/21/2011		($0.01)	$0.03			View	N/A
4/20/2011		($0.01)	$0.01			View	N/A
1/27/2011		($0.02)	$0.02			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Cepheid (NASDAQ:CPHD)

Current Year EPS Consensus Estimate: $-0.23 EPS
Next Year EPS Consensus Estimate: $0.61 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($0.26)	($0.16)	($0.21)
Q2 2016	3	($0.20)	($0.17)	($0.18)
Q3 2016	3	($0.18)	($0.11)	($0.15)
Q4 2016	2	($0.03)	($0.01)	($0.02)

(Data provided by Zacks Investment Research)

Dividend History for Cepheid (NASDAQ:CPHD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cepheid (NASDAQ:CPHD)

Insider Ownership Percentage: 4.16%
Institutional Ownership Percentage: 95.32%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/17/2016	Scott A Campbell	VP	Sell	287	$36.16	$10,377.92
8/4/2016	Scott A Campbell	VP	Sell	746	$36.71	$27,385.66
5/3/2016	Scott A Campbell	VP	Sell	2,058	$27.90	$57,418.20
5/2/2016	Peter V Farrell	EVP	Sell	390	$28.90	$11,271.00
4/28/2016	Peter V Farrell	EVP	Sell	390	$36.30	$14,157.00
4/25/2016	John L Bishop	CEO	Sell	110,000	$35.50	$3,905,000.00
3/10/2016	Peter V Farrell	EVP	Sell	393	$33.01	$12,972.93
2/8/2016	Warren C. Kocmond, Jr.	COO	Sell	292	$28.53	$8,330.76
2/1/2016	Warren C. Kocmond, Jr.	COO	Sell	351	$28.44	$9,982.44
1/22/2016	Warren C. Kocmond, Jr.	COO	Sell	157	$33.16	$5,206.12
12/10/2015	Peter V. Farrell	EVP	Sell	394	$31.67	$12,477.98
11/20/2015	Robert J Easton	Director	Sell	3,206	$36.02	$115,480.12
11/17/2015	Robert J Easton	Director	Sell	2,724	$34.84	$94,904.16
11/12/2015	Robert J Easton	Director	Sell	2,556	$35.01	$89,485.56
10/30/2015	Peter V. Farrell	EVP	Sell	1,560	$33.89	$52,868.40
8/27/2015	Peter V. Farrell	EVP	Sell	1,577	$48.67	$76,752.59
8/25/2015	Cristina Kepner	Director	Buy	10,000	$47.78	$477,800.00
6/26/2015	Warren C Kocmond Jr	COO	Sell	9,375	$61.52	$576,750.00
4/29/2015	Thomas L Gutshall	Director	Sell	1,800	$56.62	$101,916.00
4/21/2015	Joseph H Smith	EVP	Sell	91,866	$54.51	$5,007,615.66
4/20/2015	John L Bishop	CEO	Sell	100,000	$55.20	$5,520,000.00
2/25/2015	Hollings Renton	Director	Sell	9,375	$57.76	$541,500.00
2/13/2015	Dean O Morton	Director	Sell	12,500	$58.51	$731,375.00
2/3/2015	Thomas D Brown	Director	Sell	12,500	$56.29	$703,625.00
1/30/2015	Andrew Miller	CFO	Sell	6,677	$57.64	$384,862.28
1/12/2015	Andrew Miller	CFO	Sell	11,719	$56.65	$663,881.35
1/12/2015	David H Persing	EVP	Sell	5,000	$56.90	$284,500.00
1/12/2015	Warren C Kocmond Jr	COO	Sell	4,688	$57.00	$267,216.00
1/5/2015	Andrew Miller	CFO	Sell	2,250	$54.95	$123,637.50
1/5/2015	Kerry Flom	EVP	Sell	8,694	$54.21	$471,301.74
11/19/2014	Dean O Morton	Director	Sell	11,849	$52.96	$627,523.04
11/7/2014	Hollings Renton	Director	Sell	9,375	$51.07	$478,781.25
10/31/2014	Andrew Miller	CFO	Sell	12,167	$53.84	$655,071.28
10/31/2014	David H Persing	EVP	Sell	20,000	$53.34	$1,066,800.00
10/31/2014	Dean O Morton	Director	Sell	7,500	$52.64	$394,800.00
10/29/2014	Kerry Flom	EVP	Sell	7,077	$51.36	$363,474.72
10/29/2014	Thomas L Gutshall	Director	Sell	12,500	$51.63	$645,375.00
10/28/2014	David H Persing	EVP	Sell	15,000	$51.51	$772,650.00
10/3/2014	Kerry Flom	EVP	Sell	1,271	$44.52	$56,584.92
8/7/2014	Warren C Kocmond Jr	EVP	Sell	324	$38.69	$12,535.56
7/14/2014	Kerry Flom	EVP	Sell	2,812	$49.72	$139,812.64
7/3/2014	Kerry Flom	EVP	Sell	1,282	$48.97	$62,779.54
5/29/2014	Kerry Flom	EVP	Sell	4,265	$45.49	$194,014.85
5/22/2014	Warren C Kocmond Jr	EVP	Sell	1,300	$42.38	$55,094.00
4/29/2014	Kerry Flom	EVP	Sell	2,660	$42.38	$112,730.80
4/25/2014	John Bishop	CEO	Sell	107,651	$43.93	$4,729,108.43
4/22/2014	John Bishop	CEO	Sell	42,349	$46.11	$1,952,712.39
4/22/2014	Robert Easton	Director	Sell	12,500	$45.59	$569,875.00
4/3/2014	Kerry Flom	EVP	Sell	1,621	$51.55	$83,562.55
4/1/2014	Andrew Miller	CFO	Sell	4,688	$52.78	$247,432.64
3/13/2014	Andrew Miller	CFO	Sell	17,265	$55.55	$959,070.75
1/31/2014	Andrew Miller	CFO	Sell	63,375	$53.10	$3,365,212.50
1/31/2014	John Bishop	CEO	Sell	150,000	$50.67	$7,600,500.00
1/31/2014	Joseph Smith	EVP	Sell	50,000	$51.15	$2,557,500.00
1/3/2014	Kerry Flom	EVP	Sell	6,357	$45.66	$290,260.62
1/2/2014	Andrew Miller	CFO	Sell	2,437	$45.92	$111,907.04
12/23/2013	Kerry Flom	EVP	Sell	10,000	$46.51	$465,100.00
10/30/2013	David H Persing	VP	Sell	5,000	$41.35	$206,750.00
10/29/2013	Kerry Flom	EVP	Sell	2,660	$40.50	$107,730.00
10/24/2013	Thomas L Gutshall	Director	Sell	3,000	$40.07	$120,210.00
10/18/2013	David H Persing	VP	Sell	20,000	$40.59	$811,800.00
9/24/2013	Thomas Gutshall	Director	Sell	3,000	$38.97	$116,910.00
9/18/2013	David Persing	VP	Sell	5,000	$39.34	$196,700.00
9/16/2013	David Persing	VP	Sell	5,000	$38.95	$194,750.00
9/6/2013	David H Persing	VP	Sell	20,000	$37.99	$759,800.00
8/30/2013	David Persing	VP	Sell	5,129	$36.62	$187,823.98
8/26/2013	Thomas Gutshall	Director	Sell	3,000	$36.38	$109,140.00
8/21/2013	Robert Easton	Director	Sell	7,500	$35.01	$262,575.00
7/24/2013	Thomas L Gutshall	Director	Sell	3,000	$34.18	$102,540.00
6/24/2013	Thomas L Gutshall	Director	Sell	3,000	$32.91	$98,730.00
5/28/2013	Andrew Miller	CFO	Sell	22,468	$38.51	$865,242.68
5/24/2013	Thomas L Gutshall	Director	Sell	3,000	$37.90	$113,700.00
5/13/2013	Kerry Flom	EVP	Sell	6,832	$39.76	$271,640.32
3/25/2013	Thomas L Gutshall	Director	Sell	3,000	$38.28	$114,840.00
2/4/2013	Joseph H Smith	EVP	Sell	38,400	$36.20	$1,390,080.00
12/24/2012	Thomas L Gutshall	Director	Sell	3,000	$33.06	$99,180.00
11/26/2012	Thomas L Gutshall	Director	Sell	7,778	$31.94	$248,429.32

(Data available from 1/1/2013 forward)

Latest Headlines for Cepheid (NASDAQ:CPHD)

Date	Headline
	Featured Stock: Parsley Energy, Inc. (NYSE:PE), CEPHEID (NASDAQ:CPHD) - Newburgh Press (NASDAQ:CPHD) newburghpress.com - September 27 at 4:23 PM
	CEPHEID (NASDAQ:CPHD) EPS Projection For FY2016 At $0.17 (NASDAQ:CPHD) www.stocksdaily.net - September 27 at 8:58 AM
	Overbuying Stock Buzz: Cepheid (NASDAQ:CPHD) - Post Registrar (NASDAQ:CPHD) postregistrar.com - September 26 at 4:35 PM
	Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid (NASDAQ:CPHD) feeds.benzinga.com - September 26 at 2:25 PM
	Danaher: A Solid Blue Chip Stock For Value Investors (NASDAQ:CPHD) seekingalpha.com - September 26 at 9:04 AM
	Cepheid (NASDAQ:CPHD) Earnings Preview: Should Investors Be ... - The Voice Registrar (NASDAQ:CPHD) voiceregistrar.com - September 23 at 9:29 AM
	Cepheid (CPHD) Updates FY15 Earnings Guidance - Petro Global News 24 (NASDAQ:CPHD) petroglobalnews24.com - September 23 at 9:29 AM
	Cepheid's (CPHD): Volatile Movement - Hot Stocks Point (NASDAQ:CPHD) www.hotstockspoint.com - September 23 at 9:29 AM
	Cepheid Shares Up 76.4% Since SmarTrend's Buy Recommendation (CPHD) (NASDAQ:CPHD) www.mysmartrend.com - September 22 at 4:29 PM
	Investor News: Buyout of Cepheid (NASDAQ:CPHD) faces Investigation (NASDAQ:CPHD) www.groundreport.com - September 22 at 9:57 AM
	Cepheid (CPHD) Downgraded by Cowen and Company to "Market Perform" (NASDAQ:CPHD) myhealthbowl.com - September 19 at 5:11 PM
	Tech Stocks Alerts= Cepheid (NASDAQ:CPHD), Telefonaktiebolaget ... - share market updates (press release) (NASDAQ:CPHD) sharemarketupdates.com - September 15 at 4:47 PM
	Cepheid (CPHD) Announces Expanded CDT Gene Presence with Leading C. Difficile Test - StreetInsider.com (NASDAQ:CPHD) www.streetinsider.com - September 15 at 4:47 PM
	Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile Product Portfolio On The Market (NASDAQ:CPHD) www.publicnow.com - September 15 at 4:47 PM
	Cepheid Has Returned 76.1% Since SmarTrend Recommendation (CPHD) (NASDAQ:CPHD) www.mysmartrend.com - September 15 at 10:08 AM
	Cepheid's (CPHD) Shares March Higher, Can It Continue? (NASDAQ:CPHD) finance.yahoo.com - September 14 at 4:25 PM
	Two Technology Stocks Are Hot: Cepheid (CPHD), Rackspace ... - National Daily Press (NASDAQ:CPHD) www.nationaldailypress.com - September 14 at 8:42 AM
	Cepheid (CPHD) Stock Downgraded to 'Neutral' at Baird - TheStreet.com (NASDAQ:CPHD) www.thestreet.com - September 14 at 8:42 AM
	INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cepheid And Encourages Shareholders To Contact The Firm For Additional Information (NASDAQ:CPHD) finance.yahoo.com - September 13 at 9:12 AM
	Cepheid (CPHD) Stock Downgraded to 'Neutral' at Baird (NASDAQ:CPHD) www.thestreet.com - September 12 at 4:11 PM
	3 Trending Stocks: Cepheid (CPHD), Novavax, Inc. (NVAX), LendingClub Corporation (LC) - iStreetWire (NASDAQ:CPHD) istreetwire.com - September 10 at 8:58 AM
	Analysts Valuations For Two Stocks: Cepheid (NASDAQ:CPHD ... - The Voice Registrar (NASDAQ:CPHD) voiceregistrar.com - September 10 at 8:58 AM
	CEPHEID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Cepheid (CPHD) Over the ... - PR Newswire (press release) (NASDAQ:CPHD) www.prnewswire.com - September 10 at 8:58 AM
	Cepheid Acquisition May Not Be in the Best Interests of CPHD ... - PR Newswire (press release) (NASDAQ:CPHD) www.prnewswire.com - September 10 at 8:58 AM
	CEPHEID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Cepheid (CPHD) Over the Proposed Sale of the Company to Danaher Corporation (NASDAQ:CPHD) finance.yahoo.com - September 10 at 8:58 AM
	Cepheid Acquisition May Not Be in the Best Interests of CPHD Shareholders (NASDAQ:CPHD) finance.yahoo.com - September 9 at 4:13 PM
	SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Cepheid -CPHD (NASDAQ:CPHD) finance.yahoo.com - September 9 at 9:08 AM
	Cepheid (CPHD) Stock Price Target Raised at Barclays on Danaher Deal - TheStreet.com (NASDAQ:CPHD) www.thestreet.com - September 8 at 4:13 PM
	Cepheid downgraded by Citigroup (NASDAQ:CPHD) finance.yahoo.com - September 8 at 4:13 PM
	Will Cepheid's (CPHD) Buyout by Danaher be a Strategic Fit? (NASDAQ:CPHD) finance.yahoo.com - September 8 at 4:13 PM
	Cepheid – Value Analysis (NASDAQ:CPHD) : September 8, 2016 (NASDAQ:CPHD) www.capitalcube.com - September 8 at 4:13 PM
	Cepheid Targets Development of a Point of Care HIV Viral Load Test From a Few Drops of Blood (NASDAQ:CPHD) finance.yahoo.com - September 8 at 4:13 PM
	CEPHEID (CPHD) - Citigroup Downgrades Rating Lowers Price Target - Finance Daily (NASDAQ:CPHD) www.fidaily.com - September 8 at 8:08 AM
	News Recap: Carnival Corp (NYSE:CCL), Cepheid (NASDAQ:CPHD), Hess Corp. (NYSE:HES) - NYSE Journal (press release) (NASDAQ:CPHD) stockznews.com - September 8 at 8:08 AM
	Most Active Mix Cap Movers- Cepheid (NASDAQ:CPHD), HCA Holdings (NYSE:HCA), Antero Midstream Partners ... - Seneca Globe (NASDAQ:CPHD) www.senecaglobe.com - September 8 at 8:08 AM
	Cepheid (CPHD) Stock Exploding On DHR Acquisition (NASDAQ:CPHD) cnafinance.com - September 7 at 4:28 PM
	Cepheid (CPHD) Stock Rating Lowered by Needham & Company LLC (NASDAQ:CPHD) christiannewstoday.com - September 7 at 4:28 PM
	Cepheid (CPHD) Leaped To An 11-Month High After Acquired By Danaher (NASDAQ:CPHD) www.rttnews.com - September 7 at 4:28 PM
	Cepheid (CPHD) Gets FDA Clearance for Xpert TV Assay (NASDAQ:CPHD) finance.yahoo.com - September 7 at 4:28 PM
	Cepheid (CPHD) Stock Price Target Raised at Barclays on Danaher Deal (NASDAQ:CPHD) www.thestreet.com - September 7 at 4:28 PM
	What Made Cepheid Attractive to Danaher? (NASDAQ:CPHD) marketrealist.com - September 7 at 4:28 PM
	DHR to Reap $200 Million in Cost Synergies, Revenue through Buy (NASDAQ:CPHD) marketrealist.com - September 7 at 4:28 PM
	BTIG Sees Another Bidder For Cepheid 'Unlikely' (NASDAQ:CPHD) feeds.benzinga.com - September 7 at 12:26 PM
	Needham Downgrades Rating On CEPHEID (CPHD) To “Hold” - Finance Daily (NASDAQ:CPHD) www.fidaily.com - September 6 at 9:20 PM
	Benzinga's M&A Chatter for Tuesday September 6, 2016 (NASDAQ:CPHD) feeds.benzinga.com - September 6 at 8:21 PM
	Why Cepheid (CPHD), Spectra Energy Corp. (SE) and Navistar International Corp (NAV) Are 3 of Today’s Best Stocks (NASDAQ:CPHD) investorplace.com - September 6 at 5:00 PM
	Why Cepheid (CPHD), Spectra Energy Corp. (SE) and Navistar International Corp (NAV) Are 3 of Today’s Best Stocks (NASDAQ:CPHD) investorplace.com - September 6 at 4:54 PM
	CoLucid Pharmaceuticals (NYSE:CLCD), CEPHEID (NASDAQ ... - Benzinga (NASDAQ:CPHD) www.benzinga.com - September 6 at 4:16 PM
	Needham Cuts Rating On CEPHEID (CPHD) To "Hold" - Finance Daily (NASDAQ:CPHD) www.fidaily.com - September 6 at 4:16 PM
	Cepheid (NASDAQ:CPHD) Earnings Preview: Should Investors Be Nervous? - The Voice Registrar (NASDAQ:CPHD) voiceregistrar.com - September 6 at 4:16 PM